Pharmacologic Bases of Antiparkinsonian Therapy

1985 ◽  
pp. 82-92 ◽  
Author(s):  
H. G. Menge ◽  
U. Brand
Keyword(s):  
Antiparkinsonian Therapy

Antiparkinsonian Therapy

1977 ◽  
Vol 4 (3) ◽  
pp. 533-539
Author(s):  
DONALD B. CALNE
Keyword(s):  
Antiparkinsonian Therapy

scholarly journals Levodopa-Induced Dyskinesia: Facts and Fancy. What Does the MPTP Monkey Model Tell Us?

1992 ◽  
Vol 19 (S1) ◽  
pp. 134-137 ◽  
Author(s):  
Paul J. Bédard ◽  
Baltazar Gomez Mancilla ◽  
Pierre Blanchette ◽  
Céline Gagnon ◽  
Thérèse Di Paolo
Keyword(s):  
Dopamine Receptors ◽  
New Drugs ◽  
Monkey Model ◽  
Single Receptor ◽  
Denervation Supersensitivity ◽  
Drug Naïve ◽  
Methyl Phenyl Tetrahydropyridine ◽  
Antiparkinsonian Therapy ◽  
Methyl Phenyl

ABSTRACT:Levodopa-induced dyskinesia, one of the most frequent long-term side effects of antiparkinsonian therapy, is often attributed to denervation supersensitivity of dopamine receptors and perhaps more specifically the D-1 receptor. The available evidence based not only on clinico-pathological studies in patients but also on results of experiments performed on methyl-phenyl-tetrahydropyridine (MPTP)-treated monkeys suggests that the mechanisms may be more complex than heretofore believed. Thus it appears that no single receptor is the sole culprit, that some form of denervation supersensitivity is probably involved but not in the form of increased density of dopamine receptors. Moreover, other neurotransmitter systems must be considered such as GABA, excitatory aminoacids and peptides. The MPTP monkey model remains very useful for predicting the potential of new drugs for inducing dyskinesia. Such trials however must be performed in drug-naive animals.

scholarly journals Tranylcypromine Isomers and Parkinson's Disease: New Aspects of an Old Drug

1981 ◽  
Vol 74 (9) ◽  
pp. 649-652 ◽  
Author(s):  
G P Reynolds ◽  
P Riederer ◽  
M Sandler
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Plasma Concentrations ◽  
Depressive Illness ◽  
Low Doses ◽  
Mao Activity ◽  
Platelet Monoamine Oxidase ◽  
Hypertensive Reaction ◽  
Antiparkinsonian Therapy ◽  
Comparative Trials

The tranylcypromine stereoisomers have been investigated in a series of comparative trials in Parkinson's disease and the results indicate that doses below 3 mg/day, of the (+)-isomer in particular, are effective as adjuvant antiparkinsonian therapy. Biochemical results, monitoring platelet monoamine oxidase (MAO) activity and plasma concentrations of drugs and phenylethylamine, an MAO substrate, showed such low doses of the (+)-isomer to inhibit MAO without inducing the hypertensive reaction sometimes observed at higher dosage. These findings, along with the observation of substantial pharmacokinetic differences between the two isomers are discussed, particularly in relation to reports on their efficacy in depressive illness.

B12 METABOTROPIC GLUTAMATE RECEPTORS AS POTENTIAL TARGETS OF ANTIPARKINSONIAN THERAPY

2005 ◽  
Vol 16 (Supplement 1) ◽  
pp. S69
Author(s):  
K. Ossowska ◽  
J. Konieczny ◽  
J. Wardas ◽  
M. Pietraszek ◽  
S. Wolfarth ◽  
...  
Keyword(s):  
Glutamate Receptors ◽  
Metabotropic Glutamate Receptors ◽  
Metabotropic Glutamate ◽  
Antiparkinsonian Therapy

Antiparkinsonian therapy modifications in PD patients after STN DBS: A retrospective observational analysis

2008 ◽  
Vol 14 (8) ◽  
pp. 608-612 ◽  
Author(s):  
M. Zibetti ◽  
M. Pesare ◽  
A. Cinquepalmi ◽  
M. Rosso ◽  
B. Bergamasco ◽  
...  
Keyword(s):  
Observational Analysis ◽  
Antiparkinsonian Therapy ◽  
Stn Dbs
Sign in / Sign up

Export Citation Format

Share Document